Placental Transfer of Sugammadex in the Human Placental Perfusion Model
NCT ID: NCT06634355
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
16 participants
INTERVENTIONAL
2025-03-17
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta
NCT04400084
Transplacental Transfer of Drugs Used in Pregnant Women
NCT02622802
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
NCT05739123
Placental Passage and Disposition of Drugs: A Physiology-based Approach
NCT02438631
Fetus Programming and Long Active Outcomes, Interaction Between Mother, Placenta and Fetus in Perinatal and Methabolic Disbalansces-focusing Diabetic Pregnancies
NCT07337759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ex-vivo placenta perfusion
Measurement of placental transfer.
Sugammadex
In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sugammadex
In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (placenta of a) pregnant women with an uncomplicated pregnancy and delivery
Exclusion Criteria
* maternal diseases during pregnancy (including diabetes mellitus, hypertension, thyroid dysfunction), or any infection (chorioamnionitis and toxoplasmosis, other, rubella, cytomegalovirus, herpes infections, or a positive anti-HIV, anti-hepatitis B virus, or anti-hepatitis C virus serology)
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristel Van Calsteren, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Gasthuisberg
Sarah Devroe, MD, Phd
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S54819(ML8732)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.